Loading clinical trials...
Loading clinical trials...
A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma
Conditions
Interventions
sunitinib malate
Locations
1
United States
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland, Ohio, United States
Start Date
August 18, 2010
Primary Completion Date
June 20, 2013
Completion Date
February 1, 2017
Last Updated
September 14, 2018
NCT06391099
NCT06349642
NCT07300241
NCT05433142
NCT07227415
NCT06242470
Lead Sponsor
Case Comprehensive Cancer Center
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions